Details of the Drug

General Information of Drug (ID: DMNUC42)

Drug Name
Sulodexide
Indication
Disease Entry ICD 11 Status REF
Tinnitus MC41 Approved [1]
Therapeutic Class
Antithrombotic Agents
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 295.29
Logarithm of the Partition Coefficient (xlogp) 0.2
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Clearance
The clearance of drug is 2.70 +/- 0.58 L/h []
Half-life
The concentration or amount of drug in body reduced by one-half in 11.7 +/- 2.0 hours [2]
Metabolism
The drug is metabolized via the liver []
Vd
The volume of distribution (Vd) of drug is 71.24 L []
Chemical Identifiers
Formula
C12H17N5O4
IUPAC Name
(2R,3R,4R,5R)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol
Canonical SMILES
CNC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)OC
InChI
InChI=1S/C12H17N5O4/c1-13-10-7-11(15-4-14-10)17(5-16-7)12-9(20-2)8(19)6(3-18)21-12/h4-6,8-9,12,18-19H,3H2,1-2H3,(H,13,14,15)/t6-,8-,9-,12-/m1/s1
InChIKey
GRYSXUXXBDSYRT-WOUKDFQISA-N
Cross-matching ID
PubChem CID
6453528
CAS Number
57817-83-1
DrugBank ID
DB06271
TTD ID
D0E9TP

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Antithrombin-III (ATIII) TT4QPUL ANT3_HUMAN Activator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20.